Skip to main content

Table 2 Ongoing and planned combination clinical trials involving venetoclax

From: Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

Combined drugs Disease state(s) identifier Phase
Azacitidine + venetoclax Elderly, previously untreated AML NCT03466294 II
LDAC + venetoclax Treatment-naïve AML NCT02287233 I/II
LDAC + venetoclax vs LDAC + placebo Elderly; treatment-naïve AML NCT03069352 III
Cobimetinib (MEK inhibitor) + venetoclax
Idasanutlin (HDM inhibitor) + venetoclax
Elderly RR AML NCT02670044 I
Cobimetinib (MEK inhibitor) + venetoclax
Idasanutlin (MDM inhibitor) + venetoclax
RR AML NCT02670044 I
Dinaciclib + venetoclax RR AML NCT03484520 I
Alvocidib + venetoclax RR AML NCT03441555 I
Gilteritinib (FIT3 inhibitor) + venetoclax RR AML (NCT03625505) I
Quizartinib (FIT3 inhibitor) + venetoclax FLT3 mutated RR AML (NCT03735875) Ib/II
S64315 + venetoclax AML NCT03672695 I
AZD5991 + venetoclax RR AML or MDS NCT03218683 I/II
CYC065 (CDK inhibitor) + venetoclax RR AML or MDS NCT04017546 I
Alvocidib (flavopiridol) + venetoclax RR AML NCT03441555 I
Obinutuzumab + venetoclax RR or previously untreated CLL NCT01685892 I
Ibrutinib + obinutuzumab + venetoclax CLL NCT03755947 II
Acalabrutinib (BTK inhibitor) + venetoclax Newly diagnosed CLL NCT03868722 II/III
Acalabrutinib + obinutuzumab + venetoclax CLL NCT03580928 II
Zanubrutinib (BTK inhibitor) + obinutuzumab + venetoclax Previously untreated CLL or SLL NCT03824483 II
Ublituximab + umbralisib + venetoclax CLL NCT03801525 II
Duvelisib (PI3K inhibitor) + venetoclax RR CLL or SLL or RS NCT03534323 I/II
Obinutuzumab + venetoclax RR DLBCL NCT02987400 II
Ibrutinib + rituximab + venetoclax RR DLBCL NCT03136497 I
Obinutuzumab + polatuzumab vedotin (ADC against CD79b) + venetoclax RR DLBCL or FL NCT02611323 I
Rituximab + venetoclax RR FL NCT02187861 II
Obinutuzumab + ibrutinib + venetoclax RR MCL NCT02558816 I/II
Ibrutinib + venetoclax RR MCL NCT02471391 II
Ibrutinib + venetoclax vs ibrutinib + placebo MCL NCT03112174 III
Carfilzomib + dexamethasone + venetoclax RR MM NCT02899052 II
Bortezomib + dexamethasone + venetoclax vs bortezomib + dexamethasone + placebo RR MM NCT02755597 III
Pomalidomide + dexamethasone + venetoclax RR MM NCT03567616 II
  1. ADC antibody–drug conjugate, AML acute myeloid leukemia, BTK Bruton’s tyrosine kinase, CDK cyclin-dependent kinases, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, HDM2 human double minute 2, LDAC low-dose cytarabine, MDS myelodysplastic syndrome, MEK mitogen-activated protein kinase kinase, MCL mantle cell lymphoma, MM multiple myeloma, PI3K phosphatidylinositide 3-kinase, RR relapsed/refractory, RS Richter's syndrome, SLL small lymphocytic lymphoma